Cancer Research
Blocking Fructose Metabolism Shows Promise Against Pediatric Brain Cancer
New research from Johns Hopkins reveals that disrupting fructose metabolism in tumor cells could slow group 3 medulloblastoma, a deadly childhood brain cancer, offering a potential new treatment avenue.
New Study Links Breast Tissue Aging to Increased Breast Cancer Risk in Older Women
Research mapping breast tissue changes with age explains higher breast cancer rates in older women and may guide new treatments.
Advanced Heart, Kidney and Metabolic Syndrome Linked to 30% Higher Cancer Risk, Study Finds
New research published in Circulation: Population Health and Outcomes reveals that later stages of cardiovascular-kidney-metabolic (CKM) syndrome are associated with a 25-30% increased risk of cancer, highlighting the need for integrated screening.
LIXTE Biotechnology Advances Precision Cancer Treatment with Novel PP2A Inhibitor
LIXTE Biotechnology is pioneering a new approach in oncology with its lead compound LB-100, which enhances chemotherapy and radiation efficacy while reducing side effects, potentially improving patient outcomes.
Alliance Pavers Partners with M/I Homes for 2026 Pelotonia Cancer Research Home Build in Orlando
Alliance Pavers joins M/I Homes to construct a designated Pelotonia Home in Orlando, directing funds toward cancer research and local charities while matching donations to amplify community impact.
Canadian Scientists Identify Brain Cells That Fuel Glioblastoma Growth
Researchers have discovered that certain brain cells previously thought to be passive support structures actively promote glioblastoma tumor growth, potentially opening new therapeutic avenues for one of the deadliest forms of brain cancer.
Kairos Pharma Recognized for Innovation in Overcoming Cancer Drug Resistance
Kairos Pharma Ltd. has been honored with the 2026 Pinnacle Award for its pioneering work on resistance-modulating treatments that aim to enhance the effectiveness of existing cancer therapies.
LIXTE Biotechnology Advances LB-100 as a Novel Cancer Treatment Enhancer
LIXTE Biotechnology's LB-100, a first-in-class PP2A inhibitor, aims to boost the effectiveness of existing chemotherapies and immunotherapies in hard-to-treat cancers, with ongoing clinical trials for ovarian, colon, and soft tissue sarcomas.
Precision Oncology Shifts to Combination Strategies as Resistance Challenges Persist
Cancer treatment is increasingly moving toward multi-drug regimens that combine targeted therapies with immunotherapy and chemotherapy, with Lixte Biotechnology's first-in-class PP2A inhibitor LB-100 designed to enhance existing treatments by disrupting cancer cell repair and boosting immune activity.
LIXTE Biotechnology's LB-100 Represents Novel Cancer Treatment Approach Through PP2A Inhibition
LIXTE Biotechnology Holdings is advancing LB-100, a first-in-class PP2A inhibitor designed to enhance existing cancer therapies by making tumors more responsive to chemotherapy and immunotherapy in multiple clinical programs targeting solid tumors with significant unmet medical need.
Molecular Testing Gains Importance in Complex CNS Cancer Diagnosis and Treatment
Molecular analysis is becoming crucial for identifying and treating complex central nervous system tumors, which traditional methods often miss, with companies like CNS Pharmaceuticals advancing targeted drug development.
Pacylex and Heidelberg Pharma Present Promising Zelenirstat ADC Data at World ADC Conference
Pacylex Pharmaceuticals and Heidelberg Pharma are presenting data showing zelenirstat's potential as a novel antibody drug conjugate payload, demonstrating significantly increased potency against breast and prostate cancer cells compared to oral administration alone.
Oncotelic Therapeutics Featured in Editorial on Nanomedicine Advances in Oncology
Oncotelic Therapeutics' inclusion in a NetworkNewsWire editorial highlights how its Deciparticle platform represents significant progress in nanomedicine for improving cancer drug delivery and reducing toxicity.
Glioblastoma Remission Rates Remain Challenging Despite Treatment Advances
Only 25% of glioblastoma patients experience remission lasting at least two years, highlighting the urgent need for improved treatments for this aggressive brain cancer.
Study Finds mRNA COVID Vaccine May Enhance Cancer Immunotherapy Effectiveness
New research presented at the European Society for Medical Oncology conference suggests mRNA coronavirus vaccines could potentially boost the effectiveness of cancer immunotherapy treatments.
University of Calgary Seeks 10,000 Toenail Samples for Radon Exposure and Lung Cancer Study
Canadian researchers are collecting toenail samples to develop better methods for measuring radon exposure and its connection to lung cancer risk, potentially enabling earlier diagnosis and treatment.
New Research Identifies Key Mechanism Behind Cancer Immunotherapy Failures
Ohio State University researchers have discovered a previously unknown stress pathway that explains why immunotherapy fails in most cancer patients, potentially paving the way for more effective treatments.
Lund University Researchers Identify Mechanism Allowing Leukemia Cells to Evade Immune System
Researchers at Lund University have discovered why acute myeloid leukemia cells resist immunotherapy, potentially paving the way for more effective treatments for this aggressive blood cancer.
Study Reveals Common Nutrient May Enhance Cancer-Fighting Immune Cells
University of Chicago research indicates zeaxanthin, a nutrient found in common vegetables, could boost immune system effectiveness against cancer while complementary therapies like oncolytic viruses advance.
Circular DNA Fragments Identified as Key Factor in Glioblastoma Lethality
International researchers have discovered that rogue circular DNA fragments operating independently from chromosomes may explain why glioblastoma remains so deadly despite medical advances, potentially opening new treatment pathways.
Izotropic Corporation Secures $375,000 in Private Placement for Breast Cancer Imaging Development
Izotropic Corporation has closed a $375,000 private placement to fund development of its breast cancer screening technology, supporting advancements in medical imaging accuracy.
Creative Biolabs Accelerates CAR-T Therapy Innovation with Advanced Development Platform
Creative Biolabs is enhancing CAR-T therapy research through its comprehensive development platform, offering specialized viral vectors and ready-made plasmids that address critical challenges in scalability, cost, and technical efficiency for both blood cancers and emerging solid tumor applications.
Dietary Protein Restriction May Enhance Glioblastoma Treatment Efficacy, Study Finds
University of Michigan research indicates that low-protein diets combined with serine-free protein shakes could improve chemotherapy and radiation outcomes for glioblastoma patients by making tumors more vulnerable to treatment.
NCI Ends 26-Year Funding for Pediatric Brain Cancer Research Consortium
The National Cancer Institute's termination of funding for a long-running pediatric brain cancer research program highlights growing reliance on private sector entities like CNS Pharmaceuticals Inc. to advance critical childhood cancer treatments.
Youth-Created Panther Sculpture Symbolizes Community Partnership for Cancer Research
Four young artists from Boys & Girls Clubs of Broward County created a symbolic panther sculpture that merges art, community, and philanthropy to raise funds for cancer research through the Panthers on the Prowl initiative.
Wrapped in Love and Kelly Ripa Launch Limited-Edition Socks to Support Ovarian Cancer Research
Wrapped in Love and Kelly Ripa have partnered to create limited-edition teal socks with 100% of proceeds benefiting ovarian cancer research, honoring personal losses to the disease and raising awareness during Ovarian Cancer Awareness Month.
Propanc Biopharma Secures $4 Million in Public Offering to Advance Cancer Treatment Development
Propanc Biopharma has closed a $4 million public offering to fund development of its novel pancreatic proenzyme therapy targeting cancer stem cells in pancreatic, ovarian, and colorectal cancers.
Nerve Damage Identified as Unexpected Cause of Cancer Immunotherapy Resistance
A multinational research team has discovered that cancer-induced nerve damage contributes to immunotherapy resistance, potentially opening new treatment avenues for patients.
Izotropic Corporation Announces $300K Private Placement and Warrant Extension for Breast Cancer Imaging Technology
Izotropic Corporation's $300,000 private placement and warrant extension provides crucial working capital to advance its breast cancer imaging technology development.
CNS Pharmaceuticals Inc. to Showcase Innovative Cancer Treatments at Webull Financial Biotech/MedTech Webinar
CNS Pharmaceuticals Inc. (NASDAQ: CNSP) will present its groundbreaking cancer treatment research at the upcoming Webull Financial Corporate Connect Webinar Series, highlighting the potential of its drug candidate TPI 287 in treating brain and central nervous system cancers.